Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: Modulation by cross-sex hormone administration

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 11, 1998, Pages 1716-1722

  Giltay, E J ^a   Elbers, J M H ^a   Gooren, L J G ^a   Emeis, J J ^b   Kooistra, T ^b   Asscheman, H ^a   Stehouwer, C D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Insulin sensitivity; Plasminogen activator inhibitor type 1; Sex hormones; Visceral fat accumulation

Indexed keywords

CYPROTERONE ACETATE; ETHINYLESTRADIOL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; FEMALE; HUMAN; INSULIN SENSITIVITY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REGRESSION ANALYSIS; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031798097     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.11.1716     Document Type: Article

References (14)

1. Hamsten A, Walldius G, Szamosi A, Blombäck M, De Faire U, Dahlén G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-8.
2. Meade TW, Ruddock V, Stirling Y, Charkrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
3. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SO. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group. Circulation. 1996;94:2057-2063.
4. Lijnen HR, Collen D. Mechanism of physiological fibrinolysis. Baillières Clin Haematol. 1995;8:277-290.
5. Kooistra T, Bosma P, Tons H, Van Den Ende A, Meyer P, Princen H. Plasminogen activator inhibitor 1: biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.
6. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93:106-110.
7. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800-803.
8. Alessi MC, Peiretti F, Morage P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.
9. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Allan C. Fat distribution and plasminogen inhibitor activity in nondiabetic obese women. Metabolism. 1989;38:913-915.
10. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
11. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817-825.
12. Cigolini M, Targher G, Seidell JC, Schiavon R, Manara F, Zenti MG, Mattioli C, De Sandre G. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 1994;106:139-147.
13. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
14. Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol. 1997;17:553-559.